Dysmorphic syndrome due to mucopolysaccharidosis type I

被引：0
|
作者：
Mounach, J. [1 ]
Abilkassem, R. [2 ]
Satte, A. [1 ]
Ouahmane, Y. [1 ]
Berri, M. Ait [1 ]
Agadr, A. [2 ]
Ouhabi, H. [1 ]
Zerhouni, A. [1 ]
机构：
[1] Hop Mil Instruct Mohammed V, Serv Neurophysiol, Rabat, Morocco
[2] Hop Mil Instruct Mohammed V, Serv Pediat, Rabat, Morocco
来源：
ARCHIVES DE PEDIATRIE | 2014年 / 21卷 / 04期
关键词：
ENZYME REPLACEMENT THERAPY;
D O I：
10.1016/j.arcped.2014.01.006
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
[No abstract available]
引用
收藏
页码：415 / 417
页数：3
相关论文
共 50 条
  • [31] alpha-L-iduronidase therapy for mucopolysaccharidosis type I
    Tolar, Jakub
    Orchard, Paul J.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04) : 743 - 751
  • [32] Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) - a case report
    Jurecka, Agnieszka
    Rozdzynska, Agnieszka
    Marucha, Jolanta
    Czartoryska, Barbara
    Tylki-Szymanska, Anna
    PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2010, 6 (02): : 151 - 155
  • [33] Mucopolysaccharidosis type VII (Sly syndrome) - What do we know?
    Grant, Christina L.
    Lopez-Valdez, Jaime
    Marsden, Deborah
    Ezgu, Fatih
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (03)
  • [34] Fatal Coronary Artery Disease in an Infant With Severe Mucopolysaccharidosis Type I
    van den Broek, Leonie
    Backx, Ad P. C. M.
    Coolen, Hans
    Wijburg, Frits A.
    Wevers, Ron
    Morava, Eva
    Neeleman, Chris
    PEDIATRICS, 2011, 127 (05) : E1343 - E1346
  • [35] Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
    Giugliani, Roberto
    Muschol, Nicole
    Keenan, Hillary A.
    Dant, Mark
    Muenzer, Joseph
    ARCHIVES OF DISEASE IN CHILDHOOD, 2021, 106 (07) : 674 - 679
  • [36] Successful Desensitization to Idursulfase in a Patient with Type II Mucopolysaccharidosis (Hunter syndrome)
    Serrano, C. D.
    Gomez, J. F.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2011, 21 (07) : 571 - 572
  • [37] Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome)
    Stapleton, Molly
    Kubaski, Francyne
    Mason, Robert W.
    Yabe, Hiromasa
    Suzuki, Yasuyuki
    Orii, Kenji E.
    Orii, Tadao
    Tomatsu, Shunji
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 295 - 307
  • [38] Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I
    Jameson, Elisabeth
    Jones, Simon
    Remmington, Tracey
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [39] Features of Brain MRI in Dogs with Treated and Untreated Mucopolysaccharidosis Type I
    Vite, Charles H.
    Nestrasil, Igor
    Mlikotic, Anton
    Jens, Jackie K.
    Snella, Elizabeth M.
    Gross, William
    Shapiro, Elsa G.
    Kovac, Victor
    Provenzale, James M.
    Chen, Steven
    Le, Steven Q.
    Kan, Shih-hsin
    Banakar, Shida
    Wang, Raymond Y.
    Haskins, Mark E.
    Ellinwood, N. Matthew
    Dickson, Patricia I.
    COMPARATIVE MEDICINE, 2013, 63 (02) : 163 - 173
  • [40] HUNTER SYNDROME (TYPE II MUCOPOLYSACCHARIDOSIS). KEYS FOR ITS RECOGNITION AND DIAGNOSIS
    Andres, A. G. Andres
    BOLETIN DE PEDIATRIA, 2024, 64 (267):
12345